Exabis Library
Welcome to the e-CCO Library!
P445: Does The Sequence Matter ? Comparative effectiveness of a second line biologic in patients with Ulcerative Colitis: vedolizumab followed by an anti-TNF versus anti-TNF followed by vedolizumab
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P445: Early outcomes for adolescent inflammatory bowel disease patients treated in a transition clinic
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P445: Is objective disease monitoring strategy tailored to the presence of clinical symptoms, a prospective cohort study from a tertiary IBD center from Hungary
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P445: Network meta-analysis to evaluate the comparative efficacy of intravenous and subcutaneous infliximab and vedolizumab in the maintenance treatment of adult patients with Crohn's Disease and Ulcerative Colitis
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P445: Patients with active perianal fistulas have a reduced physical health compared with Crohn’s patients without perianal fistulas
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P445: Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn's disease undergoing right hemicolectomy with ileocolonic anastomosis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P445: Prevalence rates of biosimilar discontinuation and switchback to originator biologics following non-medical switching: a meta-analysis of real-world studies
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P446 Transcriptional and microbial biomarkers of response to anti-TL1A therapy in ulcerative colitis: the Phase 2a TUSCANY study
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P446: Characterization of ulcerative colitis patients in the Golimumab PURSUIT-Maintenance study: post-hoc analyses of patients who maintained and did not maintain clinical response through week 54
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P446: Dose escalation with originator infliximab is more common than standard dosing in paediatric IBD: the DEVELOP experience
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P446: Effects of CYP3A5 genotype on efficacy and safety of tacrolimus in refractory ulcerative colitis: experience from a tertiary referral centre
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P446: Long-term Clinical Effectiveness And Stoma Outcome Of Fecal Diversion In Refractory Crohn’s Proctitis
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P446: Patient and public involvement in a clinical trial for perianal Crohn’s fistula
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P446: Plasma rich in growing factors as treatment for perianal fistulas in Crohn’s disease: unicentre experience.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P446: The INTESTINE study: INtended TEmporary STomas In crohN's diseasE
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P447 No severe neonatal and maternal complications in inflammatory bowel diseases patients treated with ustekinumab or vedolizumab during pregnancy
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P447: Combined fibrin glue with infliximab therapy of postoperative anastomotic fistula in patients with Crohn`s disease:A Pilot study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P447: Early predictors of the need for surgery in patients with acute severe ulcerative colitis: results of the prospective, observational, international ESCP MASC study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P447: Infliximab trough levels are decreasing overtime in patients with inflammatory bowel disease on maintenance treatment with infliximab
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P447: Positioning of ustekinumab affects its effectiveness, drug persistence and serum exposure in Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM